Log in

NASDAQ:ASNDAscendis Pharma A/S Stock Price, Forecast & News

$145.49
-1.30 (-0.89 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$143.50
Now: $145.49
$147.00
50-Day Range
$121.36
MA: $134.72
$146.86
52-Week Range
$90.06
Now: $145.49
$150.00
Volume484,388 shs
Average Volume206,266 shs
Market Capitalization$6.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Read More
Ascendis Pharma A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.98 million
Book Value$12.62 per share

Profitability

Net Income$-244,180,000.00
Net Margins-2,231.94%

Miscellaneous

Employees216
Market Cap$6.98 billion
Next Earnings Date8/26/2020 (Estimated)
OptionableOptionable

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

How has Ascendis Pharma A/S's stock been impacted by COVID-19 (Coronavirus)?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASND shares have increased by 22.7% and is now trading at $145.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ascendis Pharma A/S?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ascendis Pharma A/S.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Ascendis Pharma A/S.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Tuesday, May, 19th. The biotechnology company reported ($1.32) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.43) by $0.11. The biotechnology company had revenue of $2.45 million for the quarter, compared to analysts' expectations of $2.66 million. Ascendis Pharma A/S had a negative return on equity of 36.56% and a negative net margin of 2,231.94%. View Ascendis Pharma A/S's earnings history.

What price target have analysts set for ASND?

11 brokerages have issued 1-year target prices for Ascendis Pharma A/S's shares. Their forecasts range from $145.00 to $208.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $172.09 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View analysts' price targets for Ascendis Pharma A/S.

Has Ascendis Pharma A/S been receiving favorable news coverage?

Media stories about ASND stock have trended extremely negative on Sunday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a news impact score of -4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAscendis Pharma A/S.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,930,000 shares, a decrease of 5.9% from the April 30th total of 2,050,000 shares. Based on an average trading volume of 228,000 shares, the days-to-cover ratio is currently 8.5 days. Currently, 4.3% of the shares of the stock are short sold. View Ascendis Pharma A/S's Current Options Chain.

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (10.24%), Orbimed Advisors LLC (6.85%), Vivo Capital LLC (4.17%), Janus Henderson Group PLC (3.89%), Wellington Management Group LLP (3.48%) and Franklin Resources Inc. (1.46%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Camber Capital Management LP, Franklin Resources Inc., State Street Corp, Orbimed Advisors LLC, Ghost Tree Capital LLC, and Wellington Management Group LLP.

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Janus Henderson Group PLC, Spyglass Capital Management LLC, Asymmetry Capital Management L.P., JPMorgan Chase & Co., New York State Common Retirement Fund, and ARS Investment Partners LLC.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $145.49.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $6.98 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.